Brokerages Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have been given a consensus recommendation of “Hold” by the six brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $32.60.

A number of research analysts have recently commented on SLN shares. Wall Street Zen raised shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Thursday, January 22nd.

Silence Therapeutics Stock Performance

Shares of NASDAQ:SLN opened at $4.45 on Thursday. The business’s 50-day simple moving average is $5.58 and its 200 day simple moving average is $5.77. The company has a market cap of $210.17 million, a P/E ratio of -3.30 and a beta of 1.35. Silence Therapeutics has a one year low of $1.97 and a one year high of $7.78.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Evelyn Partners Investment Management Services Ltd boosted its stake in shares of Silence Therapeutics by 481.3% during the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock valued at $77,000 after buying an additional 11,868 shares during the last quarter. Boothbay Fund Management LLC raised its holdings in Silence Therapeutics by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 279,637 shares of the company’s stock valued at $1,451,000 after acquiring an additional 27,216 shares in the last quarter. Two Sigma Investments LP raised its holdings in Silence Therapeutics by 6.6% in the third quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after acquiring an additional 3,935 shares in the last quarter. UBS Group AG boosted its stake in Silence Therapeutics by 34.5% during the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock valued at $1,595,000 after acquiring an additional 78,854 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in Silence Therapeutics during the 4th quarter worth $177,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.